Clinical Trials Logo

Hepatic Metastases clinical trials

View clinical trials related to Hepatic Metastases.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03369041 Active, not recruiting - Clinical trials for Colorectal Adenocarcinoma

Study of the Practice of Debiri in France

Start date: February 3, 2016
Phase:
Study type: Observational [Patient Registry]

In order to extract the profiles of patients receiving DEBIRI treatment at best, the investigators proposed the establishment of a national prospective cohort to collect information on the greatest number of patients treated with DEBIRI. This cohort will allow a better understanding of the effectiveness, tolerance, feasibility and differences of practices at national level for this approach. These data will assist in the development of clinical trials in situations that appear to be most promising in clinical practice.

NCT ID: NCT03364621 Active, not recruiting - Colorectal Cancer Clinical Trials

Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

COMPARISON
Start date: August 29, 2017
Phase:
Study type: Observational

This is a prospective study investigating the disease course of patients with colorectal cancer that have had their cancer spread to their liver. The aim of this study is find potential biomarkers for disease recurrence and therapeutic targets for prognostic information.

NCT ID: NCT02913417 Active, not recruiting - Uveal Melanoma Clinical Trials

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Start date: October 10, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy. The investigators will explore this synergy with a feasibility study of 26 patients with uveal melanoma and hepatic metastases who will receive SirSpheres Yttrium-90 selective internal hepatic radiation followed by immunotherapy with the combination of ipilimumab and nivolumab.

NCT ID: NCT00200200 Active, not recruiting - Rectal Cancer Clinical Trials

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

Start date: November 19, 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and either oxaliplatin or CPT-11, plus 5-fluorouracil and leucovorin (systemic chemotherapy) will increase disease free survival in patients who have undergone liver resection. The patient will be randomized (a computer generated decision as in the flip of a coin) to receive, or not to receive bevacizumab in addition to regional and systemic chemotherapy.